Fenofibrate has been employed in various animal models of NAFL/NASH, demonstrating its ability to improve lipid metabolism, reduce hepatocyte damage (usually assessed by AST and ALT dosage), oxidative stress, and also collagen deposition [175,176,177]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.